NEWSWIRETODAY Press Release& Newswire Distribution | HOME
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Trial Finds Patients Receiving CroFab® Antivenom Less Likely To Use Opioids for Pain Control - BTG plc announced the publication of a trial,
Trial Finds Patients Receiving CroFab® Antivenom Less Likely To Use Opioids for Pain Control


NewswireToday - /newswire/ - Philadelphia, PA, United States, 2019/04/29 - BTG plc announced the publication of a trial,"Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM) - / LSE: BTG

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BTG plc, the global healthcare company, today announced the publication of a trial,"Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM).

“In a randomized, double-blind, placebo-controlled, clinical trial of CroFab® for treatment of copperhead snakebite, patients that received CroFab® were less likely to use opioids for pain control during recovery,” said Dr. Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in copperhead snake envenomation. “This is completely consistent with antivenom’s effect on tissue injury and improved recovery. No patients reported use of opioids once they had regained full function. As the CroFab® patients recovered more quickly, they required a shorter duration of opioids.”

The secondary analysis was performed using data from a randomized clinical trial designed to determine the effect of CroFab® on limb injury recovery following mild to moderate copperhead envenomation. The original trial results were published in the Annals of Emergency Medicine in 2017 as “The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery from Copperhead snake Envenomation: A Randomized Double-Blind, Placebo-Controlled, Clinical Trial.”

“Exposure to opioids as a result of an initial prescription from the emergency department may contribute to long term opioid abuse and addiction,” said Dr. Caroline Freiermuth, Associate Professor of Emergency Medicine at the University of Cincinnati. “Patients who continue to use opioids for more than five days following an initial opioid prescription have a higher risk of ongoing opioid use at a year than those patients who have stopped. When assessing the efficacy of treatments for painful diseases such as snakebite, we should more consistently assess the treatment’s impact on opioid use as was done in this study.”

Seventy-four patients were enrolled in the parent trial. Forty-five received CroFab®. Twenty-nine received a placebo. A smaller proportion of patients treated with CroFab® reported opioid use, nearly 41 percent versus nearly 61 percent of those in the placebo group. The proportion of patients using opioids remained smaller in the CroFab® group at every follow-up time point.

The resulting model estimated the odds of using opioids after hospital discharge among those who received placebo was nearly 6 times that of those who received CroFab®.

A secondary analysis,“Early Administration of Fab Antivenom Resulted in Faster Limb Recovery in Copperhead Snake Envenomation Patients,” showing early treatment with CroFab® led to faster limb recovery was published in Clinical Toxicology in 2018. Another secondary analysis,“The Validity, Reliability and Minimal Clinically Important Difference of the Patient Specific Functional Scale in Snake Envenomation,” was published in PLOS One this year.

Real world safety data has also been published in two studies,“Acute Adverse Events Associated with the Administration of Crotalidae Polyvalent Immune Fab Antivenom within the North American Snakebite Registry,” and “Incidence of Allergic Reactions to Crotalidae Polyvalent Immune Fab,” in Clinical Toxicology in 2018. These studies demonstrated a low rate of adverse reactions (between 1.4 2.7%) in patients treated with CroFab.

Between 5,000 and 9,000 people in the U.S. seek treatment in an emergency department due to a snakebite each year. There were 2,048 calls to U.S. poison centers in 2016 for copperhead bites. There were close to another 2,000 calls in which the type of snake was not identified.

About CroFab®
CroFab® ( is the only FDA-approved treatment for all North American pit viper envenomations in adult and pediatric patients. Since 2001, CroFab has been used to treat more than 50,000 patients. It is developed through a unique manufacturing process for exceptional quality and purity. It is derived from Australian sheep, is free of prions and viruses, and produced exclusively from U.S. snakes. CroFab® has been proven to halt local effects including edema, ecchymosis, and treat the source of pain. It has been found to resolve systemic effects such as nausea, vomiting, dizziness and tachycardia. CroFab® has also been found to reduce coagulation abnormalities, such as thrombocytopenia, hyperfibrinogenemia and spontaneous bleeding.

CroFab® is indicated for the management of adults and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads, and cottonmouths/water moccasins.


Do not administer CroFab® to patients with a known history of hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia).

The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur.

To report suspected adverse reactions, contact 1-877-377-3784 or FDA at 1-800-FDA-1088 or

About BTG Pharmaceuticals
BTG Pharmaceuticals ( provides antidotes that counteract the potentially life-threatening effects associated with exposure or overexposure to certain toxins. These acute care products are typically used in emergency rooms and intensive care units to treat patients for whom there are limited or no existing treatment options. We are dedicated to delivering quality medicines that make a real difference to patients through the development, manufacture, and commercialisation of pharmaceutical products.

Contact: Greentarget - Chris Gale, Vice President
P: +1 646-695-2883 / M: +1 203-570-4681

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick NewswireToday Visibility Checker


Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Trial Finds Patients Receiving CroFab® Antivenom Less Likely To Use Opioids for Pain Control

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
Publisher Contact: Chris Sampson - 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile

Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime
BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Institute of Computer Vision/ Comp. Sciences

Visit  La Bella Bakery Artisan Bakery Arizona

  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (